Aryeh Fischer, MD
About Aryeh Fischer, MD
Aryeh Fischer, MD, is the Scientific Executive Director at Bristol Myers Squibb, with extensive experience in both academic and clinical settings, particularly in rheumatology and immunology.
Professional Title and Current Role
Aryeh Fischer, MD is currently the Scientific Executive Director at Bristol Myers Squibb. In this role, Dr. Fischer is responsible for leading scientific initiatives and overseeing research programs that drive the company's mission to discover and develop innovative medicines.
Previous Roles at Bristol Myers Squibb
Aryeh Fischer, MD has held several key positions at Bristol Myers Squibb. He was the Clinical Development Lead for Lung Fibrosis from 2021 to 2023, where he led clinical research and development initiatives aimed at advancing treatments for lung fibrosis. Prior to this, he served as the Early Development Program Lead for five months in 2021, where he focused on early-stage research and development programs.
Academic Positions and Experience
Before joining Bristol Myers Squibb, Aryeh Fischer, MD had a distinguished career in academia. From 2015 to 2019, he was an Associate Professor of Medicine at the University of Colorado School of Medicine in Aurora, Colorado. He also held multiple roles at National Jewish Health, including Chief of the Division of Rheumatology from 2012 to 2015 and Associate Professor from 2004 to 2015. His academic work primarily focused on rheumatology and immunology.
Career at University of Colorado
Aryeh Fischer, MD has an extensive history with the University of Colorado at Denver and Health Sciences Center, serving from 2002 to 2019. His long-term commitment to the university underscores his dedication to both teaching and research. Over the years, he contributed significantly to academic programs and clinical practice in rheumatology and immunology.
Transition from Academia to Industry
Aryeh Fischer, MD transitioned from academia to the pharmaceutical industry, bringing over a decade of experience in rheumatology and immunology to his roles at Bristol Myers Squibb. His expertise in translational early development has helped bridge the gap between laboratory research and clinical application, making significant contributions to the company's programs in immunology and cardiovascular research.